Clinical Core

临床核心总结 临床核心的首要目标是为大规模的 临床人群，特别强调纵向随访的受试者， 由ADRC调查人员和合作者进行的研究项目的特征主题。重要 耶鲁ADRC的临床核心的重点广泛包括细胞生物学，整合 转化神经科学，并强调当前和未来生物标本的系统存储 生物标记物研究。虽然生物标志物对阿尔茨海默病（AD）诊断和治疗的重要性 尽管靶向蛋白质组学的发展是非常值得赞赏的，但靶向蛋白质组学的最新进展尚未在该领域中部署。 耶鲁ADRC生物标志物/病理学核心和特定研究项目将寻求开发这些方法 与AD和相关疾病相关。与这些努力合作，临床核心将承担 收集广泛的生物标志物标本，横跨AD的整个光谱， 在AD的整个过程中纵向地。目标1将提供大约 500名受试者将进入核心人群，参与关于 AD的完整连续性（从临床前到痴呆）以及非AD痴呆和正常对照。一 耶鲁ADRC特别感兴趣的诊断类别是认知正常的中年（50-65）一级 具有不同APOE 4遗传风险的AD亲属。目标2将在统一数据集中招募这500名受试者 (UDS)人口并向国家阿尔茨海默病协调中心提供UDS措施 （NACC）国家研究。目标3将招募受试者参加尸检项目。目标4将提供适当的 ADRC附属临床研究的受试者。目标5将收集和分发生物标本 ADRC和其他研究人员进行生物标志物研究。这些目标将提供ADRC附属调查员 一旦在AD的最早阶段的AD痴呆中验证， 发病机制

SUMMARY FOR CLINICAL CORE The over-arching goal of the Clinical Core will be to provide research diagnostic evaluations for a large clinical population with a special emphasis on subjects who are followed longitudinally to provide well- characterized subjects for the research projects conducted by ADRC investigators and collaborators. Important focuses of the Clinical Core as for the Yale ADRC broadly include cell biology, the integration of translational neuroscience, and an emphasis on systematic storage of biospecimens for current and future biomarker studies. While the importance of biomarkers for Alzheimer's disease (AD) diagnosis and therapeutic development is well appreciated, recent advances in targeted proteomics have not been deployed in this field. The Yale ADRC Biomarker/Pathology Core and specific Research Projects will seek to develop these methods with relevance to AD and related disorders. In partnership with these efforts, the Clinical Core will undertake the collection of a wide range of biomarker specimens across the full spectrum of AD cross-sectionally and during the full course of AD longitudinally. Aim 1 will provide for the evaluation and enrollment of approximately 500 subjects who will enter the Core Population for participation in research in five diagnostic categories on the full continuum of AD (from preclinical to dementia), as well as non-AD dementias and normal controls. A diagnostic category of special interest for the Yale ADRC is cognitively normal middle-aged (50-65) first-degree relatives at varying APOE4 genetic risk for AD. Aim 2 will enroll these 500 subjects in the Uniform Data Set (UDS) population and make the UDS measures available to the National Alzheimer's Coordinating Center (NACC) for national studies. Aim 3 will enroll subjects into the Autopsy Program. Aim 4 will provide appropriate subjects for the clinical studies affiliated with the ADRC. Aim 5 will collect and distribute biological specimens to ADRC and other researchers for biomarker studies. These Aims will provide ADRC affiliated investigators the ready ability to test biomarkers once validated in AD dementia in the earliest stages of AD pathogenesis.